Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Techsphere SA de CV is a Mexican private company, with operations in MX, that manufactures pharmaceutical products.

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.

Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.

The Population Council is an international, nonprofit, non-governmental organization. The Council conducts research in biomedicine, social science, and public health and helps build research capacities in developing countries. One-third of its research relates to HIV and AIDS; while its other major program areas are in reproductive health and its relation to poverty, youth, and gender. For example, the Population Council strives to teach boys that they can be involved in contraceptive methods regardless of stereotypes that limit male responsibility in child bearing. The organization held the license for Norplant contraceptive implant, and now holds the license for Mirena intrauterine system. The Population Council also publishes the journal Population and Development Review, which reports scientific research on the interrelationships between population and socioeconomic development. It also provides a forum for discussion on related issues of public policy and Studies in Family Planning, which focuses on public health, social science, and biomedical research involving sexual and reproductive health, fertility, and family planning.

Teva Women's Health, Inc. produces a wide range of women’s healthcare products. Its products include oral contraceptives, intrauterine contraception, and hormone therapy treatments for menopause. The company is headquartered in Woodcliff Lake, NJ.

Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Orion World is a manufacturer of Orion Caramel and localized drops called Orion King Drops with four flavors, orange, pineapple, strawberry, and lemon. The company was established in 1956 by Lee Yang-Gu and is based in Seoul, Korea.

Part of Catalent, Inc., Columbia Laboratories (Bermuda) Ltd. is a Bermudian company located in Hamilton. The firm manufactures pharmaceutical products.

Caris Life Sciences, Inc. engages in the provision of biotechnology solutions. It specializes in pathology, molecular profiling, and microvesicle technology for the diagnosis and treatment of cancerous tissues. The company was founded by David D. Halbert in 2008 and is headquartered in Phoenix, AZ.